"Antimycobacterial Activity of a New Rifamycin Derivative, 3-(4-cinnamylpiperazinyl iminomethyl) Rifamycin SV (T9)."

According to the authors' abstract of an article published in Antimicrobial Agents and Chemotherapy, "The antimycobacterial activities of a new rifampin (RIF) derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9), against 20 susceptible and multidrug-resistant strains Mycobacterium tuberculosis and 20 Mycobacterium avium complex (MAC) strains were investigated. The radiometric MICs of T9 for M. tuberculosis were significantly lower than those of RIF. The MICs of T9 and RIF at which 90% of the RIF-susceptible strains were inhibited were less than or equal to 0.25 and less than or equal to 0.5 (mu)g/ml, respectively. Interestingly, T9 had lower MICs...

Want to see the full article?

• Purchase this article for only $3.00